Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly misleading investors regarding its business performance and sales forecasts during the specified Class Period [1][5]. Group 1: Company Performance - On October 23, 2025, Integer reduced its full-year 2025 sales guidance to a range of $1.840 billion to $1.854 billion, which was below prior expectations [3]. - The company anticipated net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, indicating a slowdown in growth [3]. - Management revealed that sales of three new products, including two electrophysiology devices, were expected to decline in 2026 due to slower market adoption [3]. Group 2: Stock Impact - Following the announcement of reduced sales guidance, Integer's stock price fell by $35.22 per share, or 32.3%, closing at $73.89 per share on October 23, 2025 [4]. Group 3: Allegations in the Lawsuit - The lawsuit alleges that Integer made materially false and misleading statements about its competitive position in the electrophysiology (EP) manufacturing market [5]. - It is claimed that the company overstated its visibility into customer demand and mischaracterized its EP devices as long-term growth drivers for its Cardio & Vascular segment [5]. - The lawsuit contends that the positive statements made by the company regarding its business and prospects were materially misleading and lacked a reasonable basis [5].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly making materially false statements regarding its competitive position and sales performance in the electrophysiology market during the specified Class Period from July 25, 2024, to October 22, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Integer overstated its competitive position in the electrophysiology manufacturing market and misrepresented its sales performance, particularly regarding two of its EP devices [5]. - It is alleged that Integer's positive statements about its business and growth prospects were materially false and misleading, leading to investor damages when the true situation was revealed [5]. Group 2: Class Action Participation - Investors who purchased Integer common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm for more information [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements including over $438 million secured in 2019 alone [4].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly making materially false and misleading statements regarding its competitive position and sales performance in the electrophysiology manufacturing market during the specified Class Period from July 25, 2024, to October 22, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Integer overstated its competitive position in the electrophysiology manufacturing market and mischaracterized its EP devices as long-term growth drivers for its cardio and vascular segment [5]. - It is alleged that Integer experienced a deterioration in sales for two of its EP devices, contradicting its claims of strong customer demand [5]. - The lawsuit asserts that the positive statements made by the defendants about Integer's business and prospects were materially false and misleading, leading to investor damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased Integer common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the court by February 9, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - A class action has been filed against Integer Holdings Corporation (ITGR) for allegedly misleading investors about the demand for its electrophysiology (EP) devices, which has reportedly declined significantly [2][3]. Group 1: Allegations and Market Position - The complaint claims that Integer Holdings Corporation misrepresented its market position in the growing EP market and overstated the demand for its EP devices [2]. - Contrary to the company's claims, demand for Integer's EP devices has significantly decreased, with revenue growth from these devices decelerating instead of outpacing market growth [2]. Group 2: Financial Guidance and Stock Impact - On October 23, 2025, Integer revised its full-year 2025 guidance, projecting net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026 [3]. - The company acknowledged that two of its EP devices faced slower-than-expected market adoption, which is anticipated to continue affecting demand into 2026 [3]. - Following this announcement, Integer's stock price dropped by $35.22 per share, a decline of over 32%, closing at $73.89 per share on the same day [3].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Integer Holdings Corporation (NYSE: ITGR) for the period between July 25, 2024, and October 22, 2025, due to alleged misleading statements regarding the company's competitive position and sales performance in the electrophysiology market [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Integer Holdings Corporation overstated its competitive position in the electrophysiology manufacturing market and mischaracterized its EP devices as long-term growth drivers for its cardio and vascular segment [5]. - It is alleged that Integer experienced a deterioration in sales related to two of its EP devices, contradicting its claims of strong visibility into customer demand [5]. - The lawsuit asserts that the positive statements made by the defendants about Integer's business and prospects were materially false and misleading, leading to investor damages when the true details became public [5]. Group 2: Participation Information - Investors who purchased Integer common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must file a motion with the court by February 9, 2026, to represent other class members in the litigation [1][3].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Integer Holdings Corporation common stock during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and performance [1][5]. Group 1: Class Action Details - The class action lawsuit is on behalf of purchasers of Integer common stock between July 25, 2024, and October 22, 2025 [1]. - Investors who purchased Integer common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. Group 2: Allegations Against Integer Holdings - The lawsuit alleges that Integer overstated its competitive position in the electrophysiology manufacturing market [5]. - It claims that despite Integer's assertions of strong customer demand visibility, the company was experiencing a decline in sales for two of its electrophysiology devices [5]. - The lawsuit further states that Integer mischaracterized its electrophysiology devices as long-term growth drivers for its cardio and vascular segment, leading to misleading positive statements about its business and operations [5].

Core Viewpoint - Integer Holdings Corporation is facing a class action lawsuit for allegedly making false statements and failing to disclose critical information regarding its competitive position and sales performance in the electrophysiology market [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation and covers purchasers of Integer Holdings common stock from July 25, 2024, to October 22, 2025 [1]. - Investors have until February 9, 2026, to seek appointment as lead plaintiff in the lawsuit [1][5]. - The lawsuit alleges that Integer Holdings overstated its competitive position and misrepresented the sales performance of its electrophysiology devices [3]. Group 2: Allegations and Financial Impact - The lawsuit claims that Integer Holdings experienced a deterioration in sales for two of its electrophysiology devices, contradicting its claims of strong customer demand [3]. - On October 23, 2025, Integer Holdings lowered its full-year 2025 sales guidance, which was below analysts' expectations, and projected net sales growth of -2% to 2% for 2026 [4]. - Following the announcement, the stock price of Integer Holdings fell by more than 32% [4]. Group 3: Company Background - Integer Holdings operates as a medical device contract development and manufacturing company [2]. - The company is involved in the electrophysiology market, which is experiencing growth, but Integer Holdings' position within this market has been called into question [3].

Core Viewpoint - Grabar Law Office is investigating claims against Integer Holdings, Corp. regarding potential breaches of fiduciary duties by certain officers and directors [1][3]. Group 1: Investigation Details - The investigation focuses on whether officers and directors of Integer Holdings, Corp. breached their fiduciary duties to the company [1]. - Shareholders who purchased shares prior to July 25, 2024, and still hold them can seek corporate reforms and the return of funds at no cost [2][4]. Group 2: Allegations of Misconduct - A federal securities fraud class action complaint alleges that Integer Holdings made materially false and misleading statements about its business and operations [3]. - Specific allegations include: 1. Integer overstated its competitive position in the EP manufacturing market [3]. 2. The company experienced a deterioration in sales for two of its EP devices, contrary to claims of strong customer demand [3]. 3. Integer mischaracterized its EP devices as long-term growth drivers for its C&V segment [3]. 4. Positive statements made by the defendants about the company's prospects were materially false and lacked a reasonable basis [3].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and certain officers for alleged violations of federal securities laws during the Class Period from July 25, 2024, to October 22, 2025 [1][2]. Summary by Sections Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased or acquired Integer securities during the specified Class Period [2]. - The Complaint alleges that Defendants made materially false and misleading statements and failed to disclose adverse facts about the Company's business and operations [3]. Allegations Against Integer - Integer allegedly overstated its competitive position in the expanding EP manufacturing market [8]. - Despite claims of strong visibility into customer demand, the Company was reportedly experiencing a decline in sales related to two of its EP devices [8]. - Integer mischaracterized its EP devices as a long-term growth driver for its C&V segment [8]. - Consequently, the positive statements made by Defendants regarding the Company's business and prospects were deemed materially false and misleading [8]. Investor Information - Investors who suffered losses in Integer have until February 9, 2026, to request appointment as lead plaintiff [3]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only recover costs if successful [4]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered hundreds of millions for investors [5]. - The firm emphasizes restoring investor capital and ensuring corporate accountability to maintain market integrity [5].

Summary of Perimeter Solutions Conference Call on M&A Announcement Company and Industry - **Company**: Perimeter Solutions (NYSE: PRM) - **Acquisition Target**: Medical Manufacturing Technologies LLC (MMT) - **Industry**: Medical Device Manufacturing Core Points and Arguments 1. **Acquisition Details**: Perimeter Solutions is acquiring MMT for $685 million in cash, which includes certain tax benefits. MMT is a leader in precision machinery for minimally invasive medical devices, expected to generate approximately $140 million in revenue and $50 million in EBITDA in 2025 [4][12][10]. 2. **Funding Structure**: The acquisition will be funded through $500 million of new senior secured debt financing and approximately $185 million of cash on hand. Post-acquisition, total debt is expected to be around $1.2 billion, with net debt just over $1 billion [4][12][13]. 3. **Operational Fit**: MMT aligns with Perimeter's operational pillars, focusing on high-quality industrial businesses, value driver operating strategy, and a decentralized structure. MMT's strong margins and growth potential are highlighted [5][6][8]. 4. **Market Trends**: The growth of MMT is driven by increasing adoption of minimally invasive procedures, device complexity, and machinery outsourcing. The installed base of MMT has grown at a CAGR of approximately 5% since 2016 [11][10]. 5. **Aftermarket Revenue**: Approximately 50% of MMT's revenue comes from aftermarket consumables and services, which are critical for customer compliance and quality management systems [10][11]. 6. **Regulatory Compliance**: MMT's products are specified in regulatory filings with the FDA, creating a competitive moat around the business [17][10]. 7. **Future Growth Opportunities**: There is potential for further acquisitions to broaden MMT's product suite, with a focus on tuck-in M&A to enhance customer offerings [26][28]. Additional Important Content 1. **Financial Metrics**: The acquisition price implies a purchase price multiple of approximately 14 times Adjusted EBITDA, which is considered attractive given the expected growth [12]. 2. **Capital Intensity**: MMT is expected to fit into Perimeter's relatively low capital intensity model, requiring only a few million dollars of CapEx against the projected $50 million of EBITDA [16]. 3. **Customer Relationships**: MMT has long-standing relationships with top customers, averaging 15 years, which enhances customer loyalty and revenue stability [10]. 4. **Decentralized Management**: MMT will operate as a standalone business within Perimeter's decentralized structure, allowing for operational autonomy and accountability [7][5]. 5. **Market Stability**: The end market for MMT's products is relatively steady, driven by the number of medical procedures, which supports long-term growth [24]. This summary encapsulates the key points discussed during the conference call regarding Perimeter Solutions' acquisition of MMT, highlighting the strategic fit, financial implications, and market dynamics.